GlassScriptPhysician profile
Cangwa Lin
NPI 1184388704
$9,185.59
in general payments reported to CMS, 2019-2025
41 companies · $67.56 in 2025
The $67.56 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $19.83 · 2022: $4,175 · 2023: $3,894 · 2024: $1,029 · 2025: $67.56.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,665 · Education: $326.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,664.60 |
| Education | $325.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,224.29 | 2022-2024 | Tagrisso, Imfinzi, Lynparza |
| Seagen INC. | $857.41 | 2022-2023 | Padcev, Tukysa, Adcetris |
| Lilly USA, LLC | $558.86 | 2021-2024 | Verzenio, Retevmo, Jaypirca |
| Incyte Corporation | $531.44 | 2022-2023 | Monjuvi, Pemazyre |
| E.R. Squibb & Sons, L.L.C. | $507.10 | 2022-2024 | Opdivo |
| Janssen Biotech, INC. | $492.83 | 2022-2024 | Erleada, Imbruvica, Darzalex |
| Eisai INC. | $428.42 | 2022-2024 | |
| Pfizer INC. | $425.24 | 2022-2024 | |
| Merck Sharp & Dohme LLC | $415.27 | 2022-2024 | Keytruda, Lynparza, Welireg |
| Novartis Pharmaceuticals Corporation | $392.12 | 2022-2024 | |
| Daiichi Sankyo INC. | $345.16 | 2022-2024 | Enhertu |
| Amgen INC. | $288.92 | 2022-2023 | Lumakras |
| Gilead Sciences, INC. | $275.94 | 2023-2024 | Trodelvy |
| Beigene USA, INC. | $275.00 | 2022-2023 | Brukinsa |
| Astellas Pharma US INC | $203.80 | 2022-2024 | Vyloy |
Show all 41 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Cangwa Lin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.